The merger between Standard BioTools and SomaLogic creates a diversified and scaled leader in the life sciences tools industry. The strategic rationale for this transaction centers on a "multi-omic integration" play, merging the target's technical operational depth in proteomics with the group's established mass cytometry and microfluidics platforms. This fusion effectively creates a specialized powerhouse capable of delivering clinical research insights with high throughput and data quality across approximately 50 countries. This operation allows the group to execute a definitive structural expansion of its commercial reach, leveraging substantial cross-selling opportunities between the target’s biopharmaceutical research footprint and the group’s academic research settings. By incorporating the target's innovative proteomic tools, the organization can now provide a more robust and integrated solution set for translational and clinical research. The maneuver optimizes the group's financial profile through the realization of significant cost synergies while utilizing a formidable capital structure to self-fund future growth initiatives. Ultimately, the partnership solidifies the group’s standing as a primary enabler of multi-omic innovation, bridging the gap between sophisticated laboratory-scale research and industrialized pharmaceutical development standards.

This transaction is part of the Industry & Manufacturing industry, which currently tracks an average EBITDA multiple of 10.6x since the beginning of 2026, 2.9% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.